Dr Morepen Eyes Rs 500-Crore Revenue From Wellness Business In Four Years

Dr Morepen, a wholly-owned arm of Morepen Laboratories Ltd., expects to achieve a revenue of Rs 500 crore from its newly launched wellness category over the next three to four years, according to Varun Suri, the company's chief executive officer.

Dr Morepen entered the growing wellness segment with the launch of a new weight management initiative earlier this week. The company launched LightLife, a holistic weight management programme designed to address the issue of obesity.

Talking to NDTV Profit, Suri said that within the first year, Dr Morepen is expecting a Rs 30-crore revenue from the wellness category.

“We are starting with a humble Rs 30 crore, but we feel that it (revenue) can go to about Rs 500 crore in the next three to four years. That is why we worked very hard on the whole program of making it a 360-degree programme,” he said.

The wellness category, which is currently valued at $20 billion, is poised to grow to $50 billion by 2032, Suri said. “We had to work very hard, and we have huge plans to make sure that we are a serious player in this category."

Dr Morepen sees the margins for this category at about 55%, and expects it to grow further with higher volumes. 

“We are keeping margins about 50% to 55%, which will be growing as we get more volumes,” Suri said.

At present, the company is focusing on India with LightLife, but may explore the international market in the coming period, he revealed.

“It is a great program that we have come up with. So, I'm not saying that it cannot go international, but as of now the focus would be India,” the Dr Morepen CEO said.

While talking about plans to demerge its medical devices business from the main business by the first quarter of fiscal 2026, Suri clarified that there are "no plans" for now to go public.

“We are looking at how to get the value for the category (medical devices) and make sure that this category can get all the support that it needs,” Suri said.

“No plans of going public as of now, but of course, we're seeing how to make sure that we are ahead of the game, as we have been in the past, and what's the best route to do that. So it's going to be available for everyone soon. It's on the cards. It's In the plans,” he added.

Shares of Morepen Laboratories on Friday closed 1.4% lower at Rs 87.11 apiece on the NSE, whereas the benchmark Nifty 50 ended 0.89% higher.